Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grifols, S.A.
Japan's latest batch of new drug approvals includes the country's second CAR-T therapy, along with multiple oncology drugs and a novel migraine treatments, which should all reach the market in the next few months following reimbursement price listing.
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
South Korean firm outlines R&D milestones for this year including progress with a plasma therapy for COVID-19, as well as other challenges and opportunities amid the pandemic.
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Alpha Therapeutic Corporation
- Goetech LLC
- Grifols Therapeutics, Inc.
- Talecris Biotherapeutics Inc.
- Haema AG.